Using High-definition Surface Electromyography to Diagnose and Monitor Sarcopenia in Older Adults Aged 75 and Over

What this Trial Is About

Sarcopenia is a progressive muscle disorder common in older adults, characterized by loss of muscle mass, strength, and physical performance. This condition increases risks of falls, frailty, and mortality. Researchers are exploring the use of high-definition surface electromyography HD-sEMG to develop a new, non-invasive diagnostic method for sarcopenia. The study targets people aged 75 and older who are hospitalized and suspected of having sarcopenia based on a screening questionnaire score. Participants will undergo HD-sEMG to record muscle activation signals from the rectus femoris muscle during knee movements or chair rises. Additional assessments include body composition via bioimpedancemetry and possibly DEXA scans, muscle strength tests using handgrip measurements, and physical performance evaluations. The study is descriptive and cross-sectional, conducted across multiple centers, with a planned inclusion period of 18 months and a 3-month follow-up after inclusion. Throughout the study, participants will provide data through muscle ultrasound and physical activity questionnaires. Researchers will analyze HD-sEMG signals to differentiate between sarcopenic and non-sarcopenic individuals and to monitor functional recovery and muscle parameters over time. Outcomes include correlations with muscle mass, strength, physical performance, and quality of life. The total study duration is 21 months, with assessments conducted from day 1 through day 90 after inclusion.

High-definition Surface Electromyography Markers for the Diagnosis and Monitoring of Sarcopenia